Clinical trial WO29522
A Phase III, MULTICENTER, RANDOMIZED, placebo-controlled Study OF MPDL3280A (Anti-PD-L1 Antibody) IN COMBINATION WITH NAB-PACLITAXEL COMPARED with placebo with NAB-PACLITAXEL for PATIENTS WITH previously UNtreated metastatic TRIPLE-NEGATIVE BREAST CANCER
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Roche |
| EudraCT Identifier | 2014-005490-37 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02425891 |
| Inclusion criteria | Triple negative. Metastatic. 1st Line |
| Last update |